small molecule glp 1 A small-molecule oral agonist of the human glucagon-like peptide-1 receptor Aleniglipron: An Oral, Small Molecule
Description
#AskTheIMF
An extended 12-month care plan for better treatment continuity, designed to support appetite regulation and manage sustainable weight loss
Ozempic and other GLP-1 receptor agonists can increase insulin secretion, suppress glucagon release, slow digestion, and more
Combined therapy with two classes of antidiabetic agents, namely, dipeptidyl peptidase 4 inhibitors and sodium-glucose co-transporter-2 inhibitors, target several pathophysiological pathways
Rationale Obesity remains a major global health challenge, severely affecting metabolic and cardiovascular health
Discover what causes bloating on GLP-1 wight loss treatments
